GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.
Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 11, 2024 DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 ...
The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...
[1] The purpose of this review paper is to analyze the role of the kidney in glucose homeostasis, emphasizing in SGLT2 inhibition as a new therapeutic target for diabetes management. placebo ...
Regarding the hepatic safety of canagliflozin, although, there were some studies presenting few cases of elevated alanine transaminase or aspartate transaminase most of them were related to other ...
Nov. 7, 2024 — People who work the nightshift or odd hours and eat at irregular times are more prone to weight gain and diabetes, likely due to eating patterns not timed with natural daylight ...
New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...
Eggs are a nutrient-rich food that can be a healthy part of your diet if you have diabetes. While they’re high in dietary cholesterol, this has a much smaller effect than foods high in saturated ...
Bhubaneswar: India is recognized as the diabetes capital of the world, with a high incidence of diabetes and related complications affecting millions. Poor lifestyle choices and inadequate diagnosis ...